PREScribing INFORMATION

50% Dextrose Injection, USP
70% Dextrose Injection, USP
In Pharmacy Bulk Pack

IV Fluid and Nutrient Replenisher

Baxter Corporation
Mississauga, Ontario L5N 0C2
Canada

Date of Revision: July 30, 2014

Submission Control No: 174149
Baxter, PL 146 and Viaflex are trademarks of Baxter International Inc.
50% Dextrose Injection, USP/  
70% Dextrose Injection, USP

NOT FOR DIRECT INFUSION

In Pharmacy Bulk Pack

SUMMARY PRODUCT INFORMATION
Dextrose Injections, USP are sterile, nonpyrogenic, hypertonic solutions for fluid replenishment and caloric supply in a Pharmacy Bulk Package. A Pharmacy Bulk Package is a container of sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous infusion. They contain no antimicrobial agents. Composition, osmolarity, pH, and caloric content are shown below.

Domestic Products:

Table 1

<table>
<thead>
<tr>
<th>DEX USP g/L</th>
<th>APPROX OSMOLARITY (mOsmol/L)</th>
<th>*kcal/L</th>
<th>**kJ/L</th>
<th>APPROX pH</th>
<th>CODE</th>
<th>VOLUME</th>
</tr>
</thead>
<tbody>
<tr>
<td>70% DEXTROSE INJ USP</td>
<td>700</td>
<td>3530</td>
<td>2380</td>
<td>9948.4</td>
<td>4.0</td>
<td>JB0297</td>
</tr>
</tbody>
</table>

* Dex = 3.4 kcal/g  
** 1 kcal = 4.18 kJ

Import Products:

Table 1

<table>
<thead>
<tr>
<th>Composition</th>
<th>Dextrose Hydrous, USP (g/L)</th>
<th>Osmolarity (mOsmol/L) (calc.)</th>
<th>pH</th>
<th>Caloric Content (kcal/L)</th>
<th>How Supplied</th>
</tr>
</thead>
<tbody>
<tr>
<td>50% Dextrose Injection, USP</td>
<td>500</td>
<td>2520</td>
<td>4.0 (3.2 to 6.5)</td>
<td>1710</td>
<td>Size, code, NDC 2000 mL unit</td>
</tr>
<tr>
<td>70% Dextrose Injection, USP</td>
<td>700</td>
<td>3530</td>
<td>4.0 (3.2 to 6.5)</td>
<td>2390</td>
<td>2B0296 NDC 0338-0719-06</td>
</tr>
</tbody>
</table>
The structural formula of Dextrose Hydrous, USP is:

![Dextrose Hydrous, USP](image)

The VIAFLEX plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). Exposure to temperatures above 25˚C/77˚F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period. The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly.

Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as tissue culture toxicity studies.

**ACTIONS**

Dextrose Injections, USP have value as a source of water and calories. They are capable of inducing diuresis depending on the clinical condition of the patient.

**INDICATIONS AND CLINICAL USE**

Dextrose Injections, USP are indicated as a caloric component in a parenteral nutrition regimen. They are used with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: (1) the alimentary tract cannot or should not be used, (2) gastrointestinal absorption of protein is impaired, or (3) metabolic requirements for protein are substantially increased, as with extensive burns.

**CONTRAINDICATIONS**

50% Dextrose Injection, USP and 70% Dextrose Injection, USP products are contraindicated in the following conditions:

- Patients with hypersensitivity to any ingredient in the formulation or component of the container. For more information, see DESCRIPTION section;
- Patients with known allergy to corn or corn products since dextrose in the product is purified from corn.
- Patients having intracranial or intraspinal hemorrhage;
- Patients who are severely dehydrated;
- Patients who are anuric, and in patients in hepatic coma;
- Patients with clinically significant hyperglycemia.

**WARNINGS AND PRECAUTIONS**

*These injections are for compounding only, not for direct infusion.*

**General**

Dilute before use to a concentration which will, when administered with an amino acid (nitrogen) source, result in an appropriate calorie to gram of nitrogen ratio and which has an osmolarity consistent with the route of administration.
Unless appropriately diluted, the infusion of hypertonic dextrose injection into a peripheral vein may result in vein irritation, vein damage, and thrombosis. Strongly hypertonic nutrient solutions should only be administered through an indwelling intravenous catheter with the tip located in a large central vein such as the superior vena cava.

In very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolality and possible intracerebral hemorrhage. **WARNING:** This product contains aluminum which may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

**Administration by central venous catheter should be used only by those familiar with this technique and its complications.**

To reduce the risk of HYPOglycemia after discontinuation, a gradual decrease in flow rate before stopping the infusion should be considered.

**Hypersensitivity Reactions**

Hypersensitivity/infusion reactions, including anaphylactic/anaphylactoid reactions, have been reported with Dextrose Injection, USP (see Adverse Reactions).

The infusion must be stopped immediately if any signs or symptoms of a suspected hypersensitivity reaction develop. Appropriate therapeutic countermeasures must be instituted as clinically indicated.

**Dilution and other effects on serum electrolytes**

Depending on the volume and rate of infusion and depending on a patient’s underlying clinical condition and capability to metabolize dextrose, intravenous administration of dextrose can cause:

- Hyperosmolality, osmotic diuresis and dehydration
- Hypoosmolality
- Electrolyte disturbances such as
  - Hyponatremia,
  - Hypokalemia,
  - Hypophosphatemia,
  - Hypomagnesemia,
  - overhydration/Hypervolemia and, for example, congested states, including pulmonary congestion and edema.

**Hypoosmotic hyponatremia**

Hypoosmotic hyponatremia can lead to headache, nausea, seizures, lethargy, coma, cerebral edema, and death. Acute symptomatic hyponatremic encephalopathy is considered a medical emergency.

The risk for developing hypoosmotic hyponatremia is increased, for example,

- in children
- in elderly patients
- in women
• postoperatively
• in persons with psychogenic polydipsia

The risk for developing encephalopathy as a complication of hypoosmotic hyponatremia is increased, for example,
• in pediatric patients (≤16 years of age)
• in women (in particular, premenopausal women)
• in patients with hypoxemia
• in patients with underlying central nervous system disease.

Particular caution is advised in patients at increased risk of and from water and electrolyte disturbances that could be aggravated by increased free water load, HYPERglycemia or possibly required insulin administration (see below).

Preventive and corrective measures must be instituted as clinically indicated.

HYPERglycemia

As with the intravenous administration of nutrients (e.g., glucose, amino acids and lipids) in general, metabolic complications may occur if the nutrient intake is not adapted to the patient’s requirements, or the metabolic capacity of any given dietary component is not accurately assessed. Adverse metabolic effects may arise from administration of inadequate or excessive nutrients or from inappropriate composition of an admixture for a particular patient’s needs.

Rapid administration of dextrose-containing solutions may produce substantial hyperglycemia which may result in or contribute to electrolyte losses, dehydration and hypovolemia due to osmotic diuresis and a hyperosmolar syndrome. At certain clinical conditions it also may increase the risk of hypoosmotic hyponatremia by shifting of intracellular water to extracellular space, result in serious clinical outcomes (see text under the subheading "Hypoosmotic hyponatremia" in this section).

Use with caution in critically ill patients in whom hyperglycemia commonly occurs due to diabetes, impaired glucose tolerance, impaired fasting glucose, or is stress-induced.

Hyperglycemia may increase the risk of cardiac complications, infection, systemic sepsis, acute renal failure and even death in certain clinical conditions, especially in acute stress conditions.

In order to avoid HYPERglycemia the infusion rate should not exceed the patient’s ability to utilize glucose.

To reduce the risk of HYPERglycemia-associated complications, the infusion rate must be adjusted to the level suitable to the patient’s ability to utilize glucose and/or insulin administered if blood glucose levels exceed levels considered acceptable for the individual patient.

Intravenous dextrose should be administered with caution in patients with, for example:
• impaired glucose tolerance (such as in diabetes mellitus, renal impairment, or in the presence of sepsis, trauma, or shock),
• severe malnutrition (risk of precipitating a refeeding syndrome),
• thiamine deficiency, e.g., in patients with chronic alcoholism (risk of severe lactic acidosis due to impaired oxidative metabolization of pyruvate),
• water and electrolyte disturbances that could be aggravated by increased glucose and/or free water load (see above)
• patients with ischemic stroke. HYPERglycemia has been implicated in increasing cerebral ischemic brain damage and impairing recovery after acute ischemic strokes.
• patients with severe traumatic brain injury (in particular during the first 24 hours following the trauma). Early HYPERglycemia has been associated with poor outcomes in patients with severe traumatic brain injury.
• Newborns (see Use in Pediatric Patients).
Prolonged intravenous administration of dextrose and associated HYPERglycemia may result in decreased rates of glucose-stimulated insulin secretion.

**Refeeding Syndrome**

**Liver Disorders**

Hepatobiliary disorders including cholestasis, hepatic steatosis, fibrosis and cirrhosis, possibly leading to hepatic failure, as well as cholecystitis and cholelithiasis are known to develop in some patients on parenteral nutrition. The etiology of these disorders is thought to be multifactorial and may differ between patients. Patients developing abnormal laboratory parameters or other signs of hepatobiliary disorders should be assessed early by a clinician knowledgeable in liver diseases in order to identify possible causative and contributory factors, and possible therapeutic and prophylactic interventions.

**Catheter infection and sepsis**

Infection and sepsis may occur as a result of the use of intravenous catheters to administer parenteral formulations, poor maintenance of catheters or contaminated solutions.

Immunosuppression and other factors such as HYPERglycemia, malnutrition and/or their underlying disease state may predispose patients to infectious complications.

Careful symptomatic and laboratory monitoring for fever/chills, leukocytosis, technical complications with the access device, and HYPERglycemia can help recognize early infections.

The occurrence of septic complications can be decreased with heightened emphasis on aseptic technique in catheter placement, maintenance, as well as aseptic technique in nutritional formula preparation.

**Precipitates**

Pulmonary vascular precipitates have been reported in patients receiving parenteral nutrition. In some cases, fatal outcomes have occurred. Excessive addition of calcium and phosphate increases the risk of the formation of calcium phosphate precipitates. Precipitates have been reported even in the absence of phosphate salt in the solution. Precipitation distal to the in-line filter and suspected precipitate formation in the bloodstream has also been reported.

In addition to inspection of the solution, the infusion set and catheter should also periodically be checked for precipitates.

If signs of pulmonary distress occur, the infusion should be stopped and medical evaluation initiated.

Administration of hypertonic dextrose and amino acid solutions via central venous catheter may be associated with complications which can be prevented or minimized by careful attention to all aspects of the procedure. This includes attention to solution preparation, administration and patient monitoring.

**It is essential that a carefully prepared protocol, based upon current medical practice, be followed, preferably by an experienced team.**

The package insert of the protein (nitrogen) source should be consulted for dosage and all precautionary information.

Care should be taken to avoid circulatory overload, particularly in patients with cardiac insufficiency.

These injections should be used with caution in patients with overt or subclinical diabetes mellitus.

Drug product contains no more than 25 mcg/L of aluminum.

Dextrose Injection, USP (an aqueous, i.e., electrolyte-free dextrose solution) should not be administered simultaneously with blood through the same administration set because of the possibility of pseudoagglutination or hemolysis.

**Risk of Air Embolism**

Do not connect flexible plastic containers in series in order to avoid air embolism due to possible residual air contained in the primary container.

Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in air
embolism if the residual air in the container is not fully evacuated prior to administration.

Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.

**Monitoring and Laboratory Tests**

Clinical evaluation and periodic laboratory determination are necessary to monitor changes in plasma glucose level, fluid balance, electrolyte concentrations, and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient or the rate of administration warrants such evaluation.

**Carcinogenesis and Mutagenesis**

Studies with Dextrose Injection, USP have not been performed to evaluate carcinogenic potential, mutagenic potential, or effects on fertility.

**Special Populations**

**Pregnancy and Lactation**

Animal reproduction studies have not been conducted with Dextrose Injection, USP. It is also not known whether Dextrose Injection, USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Dextrose Injection, USP should be given to a pregnant woman only if clearly needed.

Nursing Mothers: Caution should be exercised when Dextrose Injection, USP is administered to a nursing woman. Intrapartum maternal intravenous dextrose infusion may result in fetal insulin production, with an associated risk of fetal HYPERglycemia and metabolic acidosis as well as rebound HYPOglycemia in the neonate.

Healthcare practitioners should carefully consider the potential risks and benefits for each specific patient before administering.

**Pediatrics**

Dextrose is safe and effective for the stated indications in pediatric patients (see INDICATIONS AND USAGE). Because of their hypertonicity, Dextrose injections must be diluted prior to administration.

The infusion rate and volume depends on the age, weight, clinical and metabolic conditions of the patient, concomitant therapy and should be determined by the consulting physician experienced in pediatric intravenous fluid therapy.

**Pediatric Glycemia-related Issues**

Newborns – especially those born premature and with low birth weight, are at increased risk of developing hypo- or HYPERglycemia. Close monitoring during treatment with intravenous dextrose solutions is needed to ensure adequate glycemic control, in order to avoid potential long term adverse effects.

HYPOglycemia in the newborn can cause:

- prolonged seizures,
- coma, and
- cerebral injury.

HYPERglycemia has been associated with

- cerebral injury, including intraventricular hemorrhage,
- late onset bacterial and fungal infection,
- retinopathy of prematurity,
- necrotizing enterocolitis,
- bronchopulmonary dysplasia
- increased oxygen requirements,
- prolonged length of hospital stay, and
- death.

**Pediatric Hyponatremia-related Issues**

Children (including neonates and older children) are at increased risk of developing hypoosmotic hyponatremia as well as for developing hyponatremic encephalopathy.

Hypoosmotic hyponatremia can lead to headache, nausea, seizures, lethargy, coma, cerebral edema and death; therefore, acute symptomatic hyponatremic encephalopathy is considered a medical emergency.

Plasma electrolyte concentrations should be closely monitored in the pediatric population.

Rapid correction of hypoosmotic hyponatremia is potentially dangerous (risk of serious neurologic complications). Dosage, rate, and duration of administration should be determined by a physician experienced in pediatric intravenous fluid therapy.

**Geriatrics**

When selecting the type of infusion solution and the volume/rate of infusion for a geriatric patient, consider that geriatric patients are generally more likely to have cardiac, renal, hepatic, and other diseases or concomitant drug therapy.

**ADVERSE REACTIONS**

Too rapid infusion of a hypertonic dextrose solution may result in diuresis, HYPERglycemia, glycosuria and hyperosmolar coma. Continual clinical monitoring of the patient is necessary in order to identify and initiate measures for these clinical conditions.

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

Anaphylactic reaction, hypersensitivity, pyrexia, and chills have also been reported.

The list of adverse reactions in this Prescribing Information is based on postmarketing reports (see below).

If an adverse reaction does occur discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.

**Post-marketing Adverse Reactions**

The following adverse reactions have been reported in the post-marketing experience, listed by MedDRA System Organ Class (SOC), then, where feasible, by Preferred Term in order of severity.

**IMMUNE SYSTEM DISORDERS:** Hypersensitivity/infusion reactions, including Anaphylactic/Anaphylactoid reactions, including reactions with mild manifestations, e.g., Pruritus, and reactions with severe manifestations, e.g., Bronchospasm, Cyanosis, Angioedema and Hypotension; Pyrexia, Chills

**METABOLISM AND NUTRITION DISORDERS:** HYPERglycemia

**SKIN AND SUBCUTANEOUS TISSUE DISORDERS:** Rash

**GENERAL DISORDER AND ADMINISTRATION SITE CONDITIONS:** Infusion site reactions including, Infusion site phlebitis, Infusion site erythema.

Other adverse reactions reported with dextrose injection/infusions include:

- Hyponatremia, which may be symptomatic (see under the subheading “Hypoosmotic hyponatremia” in WARNINGS AND PRECAUTIONS).
- Infusion site thrombophlebitis (associated with hyperosmolar solutions).
- Adverse reactions reported with parenteral nutrition to which the dextrose component may play a causal or
contributory role include:
  o Hepatic failure, Hepatic cirrhosis, Hepatic fibrosis, Cholestasis, Hepatic steatosis, Blood bilirubin increased, Hepatic enzyme increased, Cholecystitis, Cholelithiasis
  o Pulmonary vascular precipitates

DRUG INTERACTIONS

No studies have been conducted by Baxter Healthcare Corporation.

Caution must be exercised in the administration of these injections to patients receiving corticosteroids or corticotropin.

Both the glycemic effects of Dextrose Injection, USP and its effects on water and electrolyte balance should be taken into account when using Dextrose Injection, USP in patients treated with other substances that affect glycemic control, or fluid and/or electrolyte balance.

DOSAGE AND ADMINISTRATION

Following suitable admixture of prescribed drugs, the dosage is usually dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations. See directions accompanying drugs.

Electrolyte supplementation may be indicated according to the clinical needs of the patient. As indicated on an individual basis, vitamins and trace elements and other components (including amino acids and lipids) can be added to the parenteral regimen to meet nutrient needs and prevent deficiencies and complications from developing.

50% Dextrose Injection, USP and 70 % Dextrose Injection, USP in the Pharmacy Bulk Package are intended for use in the preparation of sterile, intravenous admixtures. Additives may be incompatible with the fluid withdrawn from this container. Complete information is not available. When introducing additives to Dextrose Injection, USP, the instructions for use of the medication to be added and other relevant literature must be consulted.

Those additives known to be incompatible with these products should not be used. Consult with pharmacist if available. If in the informed judgment of the physician it is deemed advisable to introduce additives, aseptic technique must be used.

Before adding a substance or medication, verify that it is soluble and/or stable in dextrose and that the pH range of Dextrose Injection, USP is appropriate.

After addition, check for a possible color change and/or the appearance of precipitates, insoluble complexes or crystals.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Do not administer unless solution is clear and the seal is intact.

These admixed injections in VIAFLEX plastic containers are intended for intravenous administration using sterile equipment.

Use of an in-line filter is recommended during administration of all parenteral solutions where possible.

Mix thoroughly. Do not store any unused portion of Dextrose Injection, USP.

OVERDOSAGE

Excess administration of Dextrose Injection, USP can cause HYPERglycemia, adverse effects on water and electrolyte balance, and corresponding complications (see Warnings and Precautions and Adverse Reactions). For example, severe HYPERglycemia and severe dilutional hyponatremia, and their complications, can be fatal.

Interventions include discontinuation of Dextrose Injection, USP administration, dose reduction, administration of insulin and other measures as indicated for the specific clinical constellation.

Clinically significant overdose of Dextrose Injection, USP may, therefore, constitute a medical emergency.
DOSAGE FORM, COMPOSITION AND PACKAGING

How Supplied
See Table 1.

DIRECTIONS FOR USE OF VIAFLEX PLASTIC PHARMACY BULK PACKAGE CONTAINER

To Open
Tear overpouch at slit and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired.

For compounding only, not for direct infusion.

Preparation for Admixing
1. The Pharmacy Bulk Package is to be used only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area).
2. Suspend container from eyelet support.
3. Remove plastic protector from outlet port at bottom of container.
4. Attach solution transfer set. Refer to complete directions accompanying set.
   Note: The closure shall be penetrated only one time with a suitable sterile transfer device or dispensing set which allows measured dispensing of the contents.
5. The VIAFLEX plastic container should not be written on directly since ink migration has not been investigated.
   Affix accompanying label for date and time of entry notation.
6. Once container closure has been penetrated, withdrawal of contents should be completed without delay. After initial entry, maintain contents at 15˚ - 25˚C and dispense within 4 hours.

STORAGE
Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. It is recommended the product be stored at room temperature (25˚C/77˚F).

Baxter Corporation
Mississauga, ON L5N 0C2
Baxter, PL 146, Viaflex are trademarks of Baxter International Inc.
Last revised: July30, 2014